Hepatotoxicity of immunosuppressants. Diagnostic approach;Hépatotoxicité des immunosuppresseurs. Conduite diagnostique

Gastroenterologie Clinique et Biologique

Volumn 32, Issue 5 SUPPL. PART 2, 2008, Pages

  Larrey, D ^a  

^a HÔPITAL SAINT ELOI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; ETANERCEPT; HYDROXYCHLOROQUINE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 2; LEFLUNOMIDE; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OLSALAZINE; PENICILLAMINE; RAPAMYCIN; SALAZOSULFAPYRIDINE; TACROLIMUS; THALIDOMIDE; TIOGUANINE;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHOLESTATIC HEPATITIS; CHRONIC HEPATITIS; CYTOLYTIC HEPATITIS; DIAGNOSTIC TEST; DRUG EFFECT; HEPATITIS; HEPATITIS B; HEPATITIS C; HUMAN; INFECTION RISK; LIVER BIOPSY; LIVER TOXICITY;

HEPATITIS, TOXIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 50349085335     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2008.04.010     Document Type: Article

References (55)

1. Pessayre O., Larrey D., and Biour M. Drug-induced liver injury. In: Bircher J., Benhamou J.P., McIntyre N., Rizzetto M., and Rodés J. (Eds). Oxford Textbook of Clinical Hepatology. 2nd en. Vol. 2 (1999), Oxford University Press, Oxford 1261-1315
2. Zimmerman H.J. The adverse effects of drugs and other chemicals on the liver. 2nd en. (1999), Lippincott Williams and Wilkins Eds
3. Larrey D. Drug-induced liver diseases. J Hepatol 32 (2000) 77-88
4. Biour M. e-drugnews.com.
5. Farrell G.C., and Liddle C. Hepatotoxicity in the twenty-first century. Semin Liver Dis 22 (2002) 110-210 (Numéro special)
6. Andrade R.J., Lucena M.I., Fernandez M.C., Pelaez G., Pachkoria K., Garcia-Ruiz E., et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 129 (2005) 512-521
7. Bjornsson E., and Olsson R. Suspected drug-induced liver fatalities reported to the WHO database. Dig Liver Dis 38 (2006) 33-38
8. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 22 (2002) 145-155
9. Lau J.Y., Lai C.L., Lin H.J., Lok A.S., Liang R.H., Wu P.C., et al. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Q J Med 73 (1989) 911-917
10. Yeo W., Chan P.K., Zhong S., Ho W.M., Steinberg J.L., Tam J.S., et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62 (2000) 299-307
11. Zekri A.R., Mohamed W.S., Samra M.A., Sherif G.M., El-Shehaby A.M., and El-Sayed M.H. Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation. Transpl Immunol 13 (2004) 305-311
12. Vernier-Massouille G., Cosnes J., Lemann M., Marteau P., Reinish W., Laharie D., et al. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut 56 (2007) 1404-1409
13. Farrell G.C., and Larter C.Z. Nonalcoholic fatty liver disease from steatosis to cirrhosis. Hepatology 43 (2006) S99-S112
14. Larrey D. Stéatohépatite non alcoolique. Histoire naturelle et diagnostic. Gastroenterol Clin Biol 27 (2003) 793-798
15. Tinel M., Berson A., Pessayre D., Letteron P., Horsmans Y., and Larrey D. Pharmacogenetic of human erythrocyte thiopurine methyltransferase activity in a French population. Br J Clin Pharmacol 32 (1991) 729-734
16. DeLeve L.D., Shulman H.M., and McDonald G.B. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 22 (2002) 27-42
17. Davern T.J. Hepatotoxicity of immunomodulating agents and the transplant situation. In: Kaplowitz N., and DeLeve L. (Eds). Drug-induced liver disease. 2nd ed. (2007), Informa Heathcare, New York 662
18. Al Hadithy A.F., de Boer N.K., Derijks L.J., Escher J.C., Mulder C.J., and Brouwers J.R. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. Dig Liver Dis 37 (2005) 282-297
19. Yates C.R., Krynetski E.Y., Loennechen T., Fessing M.Y., Tai H.L., Pui C.H., et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 126 (1997) 608-614
20. Knowles S.R., Gupta A.K., Shear N.H., and Sauder D. Azathioprine hypersensitivity-like reactions-a case report and a review of the literature. Clin Exp Dermatol 20 (1995) 353-356
21. Horsmans Y., Rahier J., and Geubel A.P. Reversible cholestasis with bile duct injury following azathioprine therapy. A case report. Liver 11 (1991) 89-93
22. Larrey D., Fréneaux E., Berson A., Babany G., Degott C., Valla D., et al. Peliosis hepatic induced by 6-thioguanine administration. Gut 29 (1986) 1265-1269
23. DeLeve L.D., Wang X., Kuhlenkamp J.F., and Kaplowitz N. Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic veno-occlusive disease. Hepatology 23 (1996) 589-599
24. Reuben A. Methotrexate controversies. In: Kaplowitz N., and DeLeve L. (Eds). Drug-induced liver disease. 2nd ed. (2007), Informa Heathcare, New York 683-705
25. Hersh E.M., Wong V.G., Henderson E.S., and Freirich E.J. Hepatotoxic effects of methotrexate. Cancer 19 (1996) 600-606
26. Ribe J., Benkov K.J., Thung S.N., Shen S.C., and LeLeiko N.S. Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine. Am J Gastroenterol 81 (1986) 205-208
27. Marinos G., Riley J., Painter D.M., and McCaughan G.W. Sulfasalazine-induced fulminant hepatic failure. J Clin Gastroenterol 14 (1992) 132-135
28. Kassianides C., Nussenblatt R., Palestine A.G., Mellow S.D., and Hoofnagle J.H. Liver injury from cyclosporine A. Dig Dis Sci 35 (1990) 693-697
29. Lorber M.I., Van Buren C.T., Flechner S.M., Williams C., and Kahan B.D. Hepatobiliary and pancreatic complications of cyclosporine therapy in 466 renal transplant recipients. Transplantation 43 (1987) 35-40
30. Emre S., Genyk Y., Schluger L.K., Fishbein T.M., Guy S.R., Sheiner P.A., et al. Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients. Transpl Int 13 (2000) 73-78
31. Fisher A., Mor E., Hytiroglou P., Emre S., Boccagni P., Chodoff L., et al. FK506 hepatotoxicity in liver allograft recipients. Transplantation 59 (1995) 1631-1632
32. Tsamandas A.C., Jain A.B., Felekouras E.S., Fung J.J., Demetris A.J., and Lee R.G. Central venulitis in the allograft liver: a clinicopathologic study. Transplantation 64 (1997) 252-257
33. Shah S., Budev M., Blazey H., Fairbanks K., and Mehta A. Hepatic veno-occlusive disease due to tacrolimus in a single-lung transplant patient. Eur Respir J 27 (2006) 1066-1068
34. Maini R., St Clair E.W., Breedveld F., Furst D., Kalden J., Weisman M., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354 (1999) 1932-1939
35. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
36. Thayu M., Markowitz J.E., Mamula P., Russo P.A., Muinos W.I., and Baldassano R.N. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 40 (2005) 220-222
37. Li E.K., Tam L.S., and Tomlinson B. Leflunomide in the treatment of rheumatoid arthritis. Clin Ther 26 (2004) 447-459
38. Thomasset S.C., Ong S.L., and Large S.R. Post-coronary artery bypass graft liver failure: a possible association with leflunomide. Ann Thorac Surg 79 (2005) 688-689
39. Weinblatt M.E., Dixon J.A., and Falchuk K.R. Serious liver disease in a patient receiving methotrexate and leflunomide. Arthritis Rheum 43 (2000) 2609-2611
40. Sevilla-Mantilla C., Ortega L., Agundez J.A., Fernandez-Gutierrez B., Ladero J.M., and Diaz-Rubio M. Leflunomide-induced acute hepatitis. Dig Liver Dis 36 (2004) 82-84
41. Legras A., Bergemer-Fouquet A.M., and Jonville-Bera A.R. Fatal hepatitis with leflunomide and itraconazole. Am J Med 113 (2002) 352-353
42. Charatan F. Arthritis drug should be removed from market, says consumer group. Br Med J 324 (2002) 869
43. Suissa S., Ernst P., Hudson M., Bitton A., and Kezouh A. Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis. Am J Med 117 (2004) 87-92
44. Sticker B.H.C.H. Drug-induced hepatic injury. 2nd ed. (1992), Elsevier, Amsterdam, London, New-York, Tokyo
45. Makin A.J., Wendon J., Fitt S., Portmann B.C., and Williams R. Fulminant hepatic failure secondary to hydroxychloroquine. Gut 35 (1994) 569-570
46. Galvan V.G., Oltra M.R., Rueda D., Esteban M.J., and Redon J. Severe acute hepatitis related to hydroxy chloroquine in a woman with mixed connective tissue disease. Clin Rheumatol 26 (2007) 971-972
47. Clark T.E., Edom N., Larson J., and Lindsey L.J. Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. Drug Saf 24 (2001) 87-117
48. Fowler R., and Imrie K. Thalidomide-associated hepatitis: a case report. Am J Hematol 66 (2001) 300-302
49. Hanje A.J., Shamp J.L., Thomas F.B., and Meis G.M. Thalidomide-induced severe hepatotoxicity. Pharmacotherapy 26 (2006) 1018-1022
50. Sen H.N., Suhler E.B., Al-Khatib S.Q., Djalilian A.R., Nussenblatt R.B., and Buggage R.R. Mycophenolate mofetil for the treatment of scleritis. Ophthalmology 110 (2003) 1750-1755
51. Neff G.W., Ruiz P., Madariaga J.R., Nishida S., Montalbano M., Meyer D., et al. Sirolimus-associated hepatotoxicity in liver transplantation. Ann Pharmacother 38 (2004) 1593-1596
52. Niemczyk M., Wyzgal J., Perkowska A., Porowski D., and Paczek L. Sirolimus-associated hepatotoxicity in the kidney graft recipient. Transpl Int 18 (2005) 1302-1303
53. Esteve M., Saro C., Gonzalez-Huix F., Suarez F., Forne M., and Viver J.M. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 53 (2004) 1363-1365
54. Lau G.K., Yiu H.H., Fong D.Y., Cheng H.C., Au W.Y., Lai L.S., et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125 (2003) 1742-1749
55. Strasser S.I., Myerson D., Spurgeon C.L., Sullivan K.M., Storer B., Schoch H.G., et al. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology 29 (1999) 1893-1899